Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis

Autor: Jan Styczyński, Lidia Gil, Marrow Transplantation, Rafael de la Cámara, Michalina Kołodziejczak
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Oncology
Male
Epstein-Barr Virus Infections
Herpesvirus 4
Human
GVHD
Graft vs Host Disease
Disease
medicine.disease_cause
Graft-versus-host disease
immune system diseases
Recurrence
Seroepidemiologic Studies
hemic and lymphatic diseases
Overall survival
education.field_of_study
Hematology
Hematopoietic cell transplantation
Incidence (epidemiology)
Hematopoietic Stem Cell Transplantation
General Medicine
Middle Aged
Prognosis
Tissue Donors
surgical procedures
operative
Treatment Outcome
HCT
Hematologic Neoplasms
Original Article
Female
Relapse-free survival
Adult
medicine.medical_specialty
Adolescent
Population
Young Adult
Non-relapse mortality
EBV
Internal medicine
medicine
Epstein-Barr virus
Humans
Transplantation
Homologous
education
Aged
business.industry
medicine.disease
Epstein–Barr virus
Survival Analysis
Transplant Recipients
Transplantation
Relapse incidence
Serostatus
business
Zdroj: Annals of Hematology
ISSN: 1432-0584
0939-5555
Popis: Allogeneic hematopoietic cell transplant (allo-HCT) is a potentially curative therapeutic strategy that showed encouraging long-term outcomes in hematological diseases. A number of factors can influence post-transplant clinical outcomes. While Epstein-Barr virus (EBV) constitutes a trigger for development of various adverse conditions, no clinical study yet has been powered to assess the effect of EBV serostatus on the clinical outcomes in allo-HCT population. To systematically summarize and analyze the impact of donor and recipient EBV serostatus on transplant outcomes in allo-HCT recipients, meta-analyses were conducted. Selected endpoints were overall survival (OS), relapse-free survival (RFS), relapse incidence (RI), non-relapse mortality (NRM), acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), and de novo cGVHD. Three studies with 26,650 patients, transplanted for acute leukemias, lymphomas, chronic hematological malignancies, or non-malignant hematological diseases were included in the meta-analysis. In the whole population, with a total of 53,300 donors and recipients, the rate of EBV seropositivity was 85.1%, including 86.6% and 83.6% among transplant recipients and healthy donors, respectively. Donor EBV seropositivity increased the risk of cGVHD by 17%, de novo cGVHD by 14%, and aGHVD by 5%. Recipient EBV seropositivity increased the risk of cGVHD by 12%, de novo cGVHD by 17%; increased NRM by 11%, increased RI by 11%, decreased OS by 14%, and decreased RFS by 11%. In performed meta-analyses, donor and recipient EBV seropositivity was found to have a significant impact on transplant outcomes in patients after allo-HCT.
Databáze: OpenAIRE
Externí odkaz: